Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia

Leukemia Research

Volumn 28, Issue 11, 2004, Pages 1203-1211

  Yamamoto, Kouhei ^a   Abe, Shinya ^a   Nakagawa, Yasunori ^a,b   Suzuki, Kenshi ^b   Hasegawa, Maki ^a   Inoue, Miori ^a   Kurata, Morito ^a   Hirokawa, Katsuiku ^a   Kitagawa, Masanobu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

acute myelogenous leukemia; AML; Apoptosis; Bone marrow; IAP; inhibitor of apoptosis proteins; MDS; myelodysplastic syndromes; OL; overt leukemia; Overt leukemia; Survivin

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; SURVIVIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MALE; MULTIGENE FAMILY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

APOPTOSIS; BASE SEQUENCE; CELL DIVISION; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA; MYELODYSPLASTIC SYNDROMES; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 4544337632     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.03.020     Document Type: Article

References (38)

1. Delacretaz F., Schmidt P.-M., Piguet D., Bachmann F., Costa J. The FAB classification (proposals) applied to bone marrow biopsy. Am. J. Clin. Pathol. 87:1987;180-186
2. Jacobs A. Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications. J. Clin. Pathol. 38:1985;1201-1207
3. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:1999;3835-3849
4. Parcharidou A., Raza A., Economopoulos T., Papageorgiou E., Anagnostou D., Papadaki T., et al. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur. J. Haematol. 62:1999;19-26
5. Fontenay-Roupie M., Bouscary D., Guesnu M., Picard F., Melle J., Lacombe C., et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br. J. Haematol. 106:1999;464-473
6. Kitagawa M., Yamaguchi S., Takahashi M., Tanizawa T., Hirokawa K., Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia. 12:1998;486-492
7. Kitagawa M., Saito I., Kuwata T., Yoshida S., Yamaguchi S., Takahashi M., et al. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 11:1997;2049-2054
8. Gupta P., Niehans G.A., LeRoy S.C., Gupta K., Morrison V.A., Schultz C. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia and predicts survival. Leukemia. 13:1999;44-53
9. Kitagawa M., Takahashi M., Yamaguchi S., Inoue M., Ogawa S., Hirokawa K., et al. Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. Leukemia. 13:1999;699-703
10. Sawanobori M., Yamaguchi S., Hasegawa M., Inoue M., Suzuki K., Kamiyama R., et al. Expression of TNF receptors and related signaling molecules in the bone marrow form patients with myelodysplastic syndromes. Leuk. Res. 27:2003;583-591
11. Kitagawa M., Kamiyama R., Takemura T., Kasuga T. Bone marrow analysis of myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia. Virchows Arch. B: Cell Pathol. 57:1989;47-53
12. Kitagawa M., Kamiyama R., Kasuga T. Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. Hum. Pathol. 24:1993;359-363
13. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 17:1998;3247-3259
14. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:1998;5315-5320
15. Shin S., Sung B.-J., Cho Y.-S., Kim H.-J., Ha N.-C., Hwang J.-I., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 40:2001;1117-1123
16. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3:1997;917-921
17. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptotic gene survivin in human and mouse differentiation. Am. J. Pathol. 152:1998;43-49
18. Velculescu V.E., Madden S., Zhang L., Lash A.E., Yu J., Rago C., et al. Analysis of human transcriptomes. Nat. Genet. 23:1999;387-388
19. Altieri D.C., Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest. 79:1999;1327-1333
20. Gianani R., Jarboe E., Orlicky D., Frost M., Bobak J., Lehner R. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol. 32:2001;119-125
21. Kawasaki H., Toyoda M., Shinohara H., Okuda J., Watanabe I., Yamamoto T., et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 91:2001;2026-2032
22. Okada E., Murai Y., Matsui K., Ishizawa S., Cheng C., Masuda M., et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 163:2001;109-116
23. Rodriguez J.A., Span S.W., Ferreira C.G.M., Kruyt F.A.E., Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp. Cell. Res. 275:2002;44-53
24. Nakagawa Y., Yamaguchi S., Hasegawa M., Nemoto T., Inoue M., Suzuki K., et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk. Res. 28:2004;487-494
25. Rothe M., Pan M.G., Henzei W.J., Ayres T.M., Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 83:1995;1243-1252
26. Duckett C.S., Nava V.E., Gedrich R.W., Clem R.J., Van Dongen J.L., Gilfillan M.C., et al. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J. 15:1996;2685-2694
27. Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G., et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 379:1996;349-353
28. Roy N., Dereraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. The cIAP-1 and cIAP-2 proteins are distinct inhibitors of specific caspases. EMBO J. 16:1997;6914-6925
29. Kitagawa M., Yamaguchi S., Takahashi M., Tanizawa T., Hirokawa K., Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia. 12:1998;486-492
30. Badran A., Yoshida A., Wano Y., Mutoh M., Imamura S., Yamashita T., et al. Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int. J. Oncol. 22:2003;59-64
31. Moriai R., Asanuma K., Kobayashi D., Yajima T., Yagihashi A., Yamada M., et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res. 21:2001;595-600
32. Adida C., Recher C., Raffoux E., Daniel M.T., Taksin A.L., Rousselot P., et al. Expression and prognostic significance of survivin in de novo acute myeloid leukemia. Br. J. Haematol. 111:2000;196-203
33. Granziero L., Ghia P., Circosta P., Gottardi D., Strola G., Geuna M., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 97:2001;2777-2783
34. Vogel L.A., Noelle R.J. CD40 and its crucial role as a member of the TNFR family. Semin. Immunol. 10:1998;435-442
35. Fluckinger A.C., Rossi J.F., Bussel A., Bryon P., Banchereau J., Defance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood. 80:1992;3173-3181
36. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53A. J. Biol. Chem. 277:2002;3247-3257
37. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2002;2613-2622
38. Kitagawa M., Yoshida S., Kuwata T., Tanizawa T., Kamiyama R. p53 expression in myelodysplastic syndromes: association with evolution of overt leukemia. Am. J. Pathol. 145:1994;338-344